What to know
- NOPARK did not support NR as a Parkinson disease-modifying treatment.
- The 2026 amnestic-MCI pilot raised blood NAD without significant cognitive improvement.
- Ingredient clarity is useful; it does not establish a memory benefit.
The clinical result matters more than the pathway
NR research has reached the brain, but it has not established a general brain-health benefit for shoppers. The October 2026 NOPARK trial found no clinical benefit in early Parkinson disease; a separate 2026 pilot in amnestic mild cognitive impairment did not significantly improve cognition. Those findings deserve space beside earlier reports of increased NAD. A molecule can reach a biological target while the hoped-for clinical outcome fails to follow. [1] [3]
This is a question about oral nicotinamide riboside. It cannot be answered by substituting a different precursor, a home NAD injection or an infusion package. Keep the ingredient name attached to the claim.
Why the early Parkinson study attracted attention
NADPARK was a phase I experiment assessing safety, cerebral NAD and brain metabolism in Parkinson disease. It reported increased cerebral NAD and metabolic effects after oral NR. That established an interesting human biological response. It did not establish that NR slows the disease, and its short exploratory design was not a substitute for a longer clinical-outcome trial. [2]
The distinction is useful beyond neurology. A brain measurement sounds closer to a brain benefit than a blood measurement does. It is closer to the organ, but it remains a measurement with a defined meaning. Location alone does not turn it into proof of better daily function.
NOPARK changed the weight of the evidence
Published on October 8, 2026, NOPARK randomized 410 people with early Parkinson disease to oral NR, 500 mg twice daily, or placebo for 52 weeks. The primary analysis included 393 participants. The adjusted difference in change on the MDS-UPDRS parts I–III was 2.72 points, favoring placebo. The authors concluded that the findings do not support NR as a disease-modifying treatment. [1]
That difference should be described accurately: it favored placebo statistically, while its size was smaller than the clinically important change thresholds reported in the abstract. It is evidence against selling this regimen as demonstrated disease modification, without becoming a claim that every NR user experiences harm.
The memory trials answer another question
A 2023 randomized pilot enrolled 20 older adults with mild cognitive impairment and escalated NR to 1 g daily during a ten-week study. Its small size and safety focus limit conclusions about cognitive benefit. In 2026, another randomized pilot in amnestic mild cognitive impairment reported increased blood NAD after twelve weeks but no significant improvement in cognitive function, whole-brain perfusion or cardiovascular function. [3] [4]
Parkinson disease and mild cognitive impairment are not interchangeable populations. The useful connection is methodological: a laboratory response must be read beside the actual functional endpoint. Neither trial provides a reason to promise sharper memory to a healthy supplement buyer.
A null trial is not an invitation to invent a better formula
A seller may respond that another amount, longer duration or delivery technology could work differently. That is a testable hypothesis. It is not a favorable result. To assess it, look for a controlled human study of that preparation with an appropriate cognitive outcome, rather than a claim that a capsule bypasses the limitation of an inconvenient trial.
The same applies to combination products. Adding resveratrol, pterostilbene or other ingredients creates another intervention. An appealing rationale cannot identify which component helps, whether the combination improves cognition, or whether it reproduces the tested exposure. More ingredients mean more assumptions unless the finished formula has relevant data.
What this means for comparing products
An NR capsule can still be compared on ingredient identity, label clarity, serving count and purchase terms. Those are real differences. They belong in a different column from demonstrated prevention or treatment of neurological disease. Tru Niagen and Basis, for example, provide a useful formulation comparison without needing to be ranked as memory therapies.
Keep the financial decision proportionate to the claim you can defend. A larger prepaid supply may lower an allocated monthly cost, but it does not improve the evidence. An injection appointment likewise buys a different service, not a result established by these oral NR trials.
A useful conclusion for a worried reader
New memory problems or a diagnosed neurological condition deserve a clinical discussion centered on that concern. Bring the exact product and the claim being considered. Ask whether the evidence supports the desired outcome in that population, and whether taking the product would alter established care or eligibility for research.
For ordinary shopping, the decisive point is simpler: clear formulation earns credit; a brain-health promise still needs an outcome. The latest trials make it less reasonable to sell an NAD rise as if it already settled the question of cognition or disease progression.
Sources
- Brakedal et al. (2026): NOPARK randomized phase 3 Parkinson disease trial (opens in a new tab)
- Brakedal et al. (2022): NADPARK phase I trial (opens in a new tab)
- Martens et al. (2026): randomized NR pilot in amnestic mild cognitive impairment (opens in a new tab)
- Orr et al. (2023): randomized NR pilot in mild cognitive impairment (opens in a new tab)
Research describes groups and specific study conditions. Your medical history, symptoms and treatment decisions require advice from your own qualified clinician.
